Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03788746 · ClinicalTrials.gov registry record
Prevalence of PD-L1 Expression in Patients With Advanced Urothelial Carcinoma
A clinical trial of Urothelial Carcinoma, sponsored by AstraZeneca.
- Completed
- Registry status
- 181
- Enrollment target
- 20
- Study locations
NCT03788746: Completed study of Urothelial Carcinoma, sponsored by AstraZeneca.
NCT03788746 is a study of Urothelial Carcinoma that has completed, run by AstraZeneca. The registered enrollment target is 181 participants, below the 237-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (24% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03788746, a study of Urothelial Carcinoma, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 181 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the prevalence of pre-treatment tumor tissue PD-L1 expression in patients diagnosed with advanced urothelial carcinoma.
Primary Outcome
The proportion of advanced UC patients with biomarker PD-L1 high results will be calculated.
Conditions Studied
Study Locations (20)
California
- Research Site - Glendale
- Research Site - Los Angeles
- Research Site - Los Angeles
- Research Site - Monterey
- Research Site - Santa Rosa
Illinois
- Research Site - Geneva
- Research Site - Harvey
- Research Site - Lake Barrington
- Research Site - Naperville
Florida
- Research Site - Boca Raton
- Research Site - Hialeah
- Research Site - Jacksonville
Colorado
- Research Site - Denver
- Research Site - Englewood
Connecticut
- Research Site - Hartford
- Research Site - Stamford
Georgia
- Research Site - Augusta
- Research Site - Roswell
Arkansas
- Research Site - Little Rock
Indiana
- Research Site - Greenwood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 2019-01-17 |
| Est. Completion | 2023-05-25 |
What the finished NCT03788746 record still lists
NCT03788746 is an observational study that tracks outcomes without assigning an intervention. The registered 181 participants enrollment target is mid-sized for trials with a published cap, below the 237-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (24% lower).
The record links to 1 condition, with Urothelial Carcinoma appearing as the primary indexed condition, and to 0 interventions.
NCT03788746 names 20 study sites across 8 states, led by California, Illinois, Florida.
Frequently Asked Questions
What is clinical trial NCT03788746 about?
NCT03788746 is a clinical study titled "Prevalence of PD-L1 Expression in Patients With Advanced Urothelial Carcinoma". The purpose of this study is to assess the prevalence of pre-treatment tumor tissue PD-L1 expression in patients diagnosed with advanced urothelial carcinoma.
What is the current status of trial NCT03788746?
This trial is currently completed. The enrollment target is 181 participants. The study started on 2019-01-17. Estimated completion is 2023-05-25.
What conditions does trial NCT03788746 study?
This clinical trial studies the following conditions: Urothelial Carcinoma.
Who is sponsoring clinical trial NCT03788746?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03788746 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urothelial Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03788746's enrollment target sits among peer trials
181 25th of 85 higher than 61 of 85 other Urothelial Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Urothelial Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Detection and Risk Stratification in Veterans Presenting With Microscopic Hematuria
RECRUITING
-
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
RECRUITING · Phase 3
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
RECRUITING · Phase 2
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04578392 · 181 participants · NA
MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's DiseaSe (SPARES)
- NCT05597891 · 181 participants · NA
Endovascular Engineering ENGULF Study
- NCT03897998 · 182 participants · Phase 2
Neural Correlates of Hypoalgesia Driven by Observation
- NCT04300556 · 182 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI